XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 272,000us-gaap_AllocatedShareBasedCompensationExpense	$ 84,000us-gaap_AllocatedShareBasedCompensationExpense	$ 750,000us-gaap_AllocatedShareBasedCompensationExpense	$ 385,000us-gaap_AllocatedShareBasedCompensationExpense
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	1,129,000rswn_UnrecognizedShareBasedCompensationExpenses / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember
Weighted average remaining years to vest	2 years 2 months 23 days
Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	194,000rswn_UnrecognizedShareBasedCompensationExpenses / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember
Weighted average remaining years to vest	1 year 9 months 15 days
Research and Development Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	107,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember	52,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember	297,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember	155,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember
Research and Development Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	8,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember	29,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember	26,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember	29,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember
General and Administrative Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	138,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember	58,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember	371,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember	116,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_LuoxisDiagnosticsMember
General and Administrative Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 19,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember	$ (55,000)us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember	$ 56,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember	$ 85,000us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember / us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember / dei_LegalEntityAxis = rswn_VyrixPharmaceuticalsIncMember

X

- Definition

Unrecognized Share Based Compensation Expenses

+ References

No definition available.

+ Details

Name:	rswn_UnrecognizedShareBasedCompensationExpenses
Namespace Prefix:	rswn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901



Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: